Works matching DE "SODIUM-glucose cotransporters"
Results: 1880
Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy.
- Published in:
- 2017
- By:
- Publication type:
- Letter to the Editor
Addressing free fatty acid receptor 1 (FFAR1) activation using supervised molecular dynamics.
- Published in:
- Journal of Computer-Aided Molecular Design, 2020, v. 34, n. 11, p. 1181, doi. 10.1007/s10822-020-00338-6
- By:
- Publication type:
- Article
Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials.
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 10, p. 1453, doi. 10.1007/s00228-021-03147-4
- By:
- Publication type:
- Article
SGLT2 inhibitors and euglycemic diabetic ketoacidosis.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution.
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 9, p. 1397, doi. 10.1007/s00228-021-03107-y
- By:
- Publication type:
- Article
Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 5, p. 651, doi. 10.1007/s00228-020-03051-3
- By:
- Publication type:
- Article
National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 12, p. 1723, doi. 10.1007/s00228-019-02751-9
- By:
- Publication type:
- Article
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 11, p. 1481, doi. 10.1007/s00228-019-02732-y
- By:
- Publication type:
- Article
FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use.
- Published in:
- Patient Care (Online), 2024, p. 1
- By:
- Publication type:
- Article
QSAR Studies of Sodium/Glucose Co-Transporter 2 Inhibitors as Potent Anti-Diabetic Drug Agents.
- Published in:
- Theoretical Foundations of Chemical Engineering, 2023, v. 57, p. S51, doi. 10.1134/S004057952307014X
- By:
- Publication type:
- Article
Flozyny jako jeden z „czterech filarów” terapii niewydolności serca.
- Published in:
- Heart & Vascular Diseases / Choroby Serca & Naczyn, 2023, v. 20, n. 2/3, p. 92, doi. 10.5603/chsin.97793
- By:
- Publication type:
- Article
Let's Be Clear about Expected Cardiovascular Risk: A Commentary on the Massive Rise in LDL Cholesterol Induced by Carbohydrate Restriction in the Proposed "Lean Mass Hyper-Responder" Phenotype.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
A Review of GLP-1RAs & SGLT-2is in Type 2 Diabetes.
- Published in:
- Family Doctor: A Journal of the New York State Academy of Family Physicians, 2020, v. 9, n. 2, p. 10
- By:
- Publication type:
- Article
Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor.
- Published in:
- Endocrine Research, 2013, v. 38, n. 3, p. 168, doi. 10.3109/07435800.2012.746364
- By:
- Publication type:
- Article
Commonly used systemic drugs interfering with bone remodeling: a case report and literature review.
- Published in:
- Quintessence International, 2021, v. 52, n. 10, p. 880, doi. 10.3290/j.qi.b2053577
- By:
- Publication type:
- Article
Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy: a meta-analysis of double-blind randomized controlled trials.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2021, v. 25, n. 2, p. 914
- By:
- Publication type:
- Article
Evogliptin attenuates bleomycin-induced lung fibrosis via inhibiting TGF-β/Smad signaling in fibroblast.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2020, v. 24, n. 20, p. 10790
- By:
- Publication type:
- Article
The effects of a sodium-glucose cotransporter 2 inhibitor on diabetic nephropathy and serum oxidized low-density lipoprotein levels.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2018, v. 22, n. 12, p. 3994
- By:
- Publication type:
- Article
Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2017, v. 21, n. 1, p. 199
- By:
- Publication type:
- Article
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors during Ramadan Fasting: Evidence, Perceptions and Guidelines.
- Published in:
- Journal of Fasting & Health, 2016, v. 4, n. 2, p. 64
- By:
- Publication type:
- Article
Exploring the Pleiotropic Genes and Therapeutic Targets Associated with Heart Failure and Chronic Kidney Disease by Integrating metaCCA and SGLT2 Inhibitors' Target Prediction.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/4229194
- By:
- Publication type:
- Article
Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 5, p. 592, doi. 10.3390/biom14050592
- By:
- Publication type:
- Article
Muscle-Specific Ablation of Glucose Transporter 1 (GLUT1) Does Not Impair Basal or Overload-Stimulated Skeletal Muscle Glucose Uptake.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 12, p. 1734, doi. 10.3390/biom12121734
- By:
- Publication type:
- Article
Renal Metabolome in Obese Mice Treated with Empagliflozin Suggests a Reduction in Cellular Respiration.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 9, p. 1176, doi. 10.3390/biom12091176
- By:
- Publication type:
- Article
Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker.
- Published in:
- Clinical & Translational Medicine, 2021, v. 11, n. 6, p. 1, doi. 10.1002/ctm2.470
- By:
- Publication type:
- Article
A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i).
- Published in:
- 2020
- By:
- Publication type:
- Letter
Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review.
- Published in:
- 2016
- By:
- Publication type:
- Erratum
Use of sodium–glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.
- Published in:
- Geriatrics & Gerontology International, 2018, v. 18, n. 1, p. 108, doi. 10.1111/ggi.13149
- By:
- Publication type:
- Article
Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.993869
- By:
- Publication type:
- Article
Response to letter from Du et al. regarding article 'Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?'.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 630, doi. 10.1111/dom.14913
- By:
- Publication type:
- Article
Sodium‐glucose cotransporter‐2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 628, doi. 10.1111/dom.14878
- By:
- Publication type:
- Article
Ethnicity and risks of severe COVID‐19 outcomes associated with glucose‐lowering medications: A cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 611, doi. 10.1111/dom.14872
- By:
- Publication type:
- Article
Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 (SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs): A pooled analysis of type 2 diabetes trials
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 166, doi. 10.1111/dom.14859
- By:
- Publication type:
- Article
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2469, doi. 10.1111/dom.14836
- By:
- Publication type:
- Article
Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2459, doi. 10.1111/dom.14832
- By:
- Publication type:
- Article
Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open‐label, crossover, active‐comparator FIORE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2319, doi. 10.1111/dom.14816
- By:
- Publication type:
- Article
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2071, doi. 10.1111/dom.14805
- By:
- Publication type:
- Article
Effects of sodium‐glucose cotransporter‐2 inhibitors and aldosterone antagonists, in addition to renin‐angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta‐analysis
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2159, doi. 10.1111/dom.14801
- By:
- Publication type:
- Article
Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2138, doi. 10.1111/dom.14799
- By:
- Publication type:
- Article
Sodium‐glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1897, doi. 10.1111/dom.14818
- By:
- Publication type:
- Article
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 2017, doi. 10.1111/dom.14789
- By:
- Publication type:
- Article
Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1950, doi. 10.1111/dom.14779
- By:
- Publication type:
- Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
- By:
- Publication type:
- Article
A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1800, doi. 10.1111/dom.14766
- By:
- Publication type:
- Article
Comparative cardiovascular effectiveness of glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes: A population‐based cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1623, doi. 10.1111/dom.14741
- By:
- Publication type:
- Article
Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1598, doi. 10.1111/dom.14735
- By:
- Publication type:
- Article
Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A narrative review and proposed clinical approach.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 969, doi. 10.1111/dom.14675
- By:
- Publication type:
- Article
Cardiovascular outcomes associated with prescription of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with diabetes and chronic kidney disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 928, doi. 10.1111/dom.14657
- By:
- Publication type:
- Article
Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 881, doi. 10.1111/dom.14646
- By:
- Publication type:
- Article
Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 816, doi. 10.1111/dom.14639
- By:
- Publication type:
- Article